Chemotherapy-induced anaemia Cancer Malignant neoplasms of female genital organs
Conditions
Interventions
Study group: Iron sucrose 200 mg intravenous drip over 30 minutes as a single dose
Control group: Ferrous sulphate 200 mg oral three times a day until the next cycle of chemotherapy
Patients will be
Sponsors
Chulalongkorn University (Thailand)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female participants aged 20 - 65 years 2. Normal liver function 3. Normal kidney function 4. No prior radiotherapy or having received radiotherapy 5. At least one remaining cycle of chemotherapy
Exclusion criteria
Exclusion criteria: 1. Iron hypersensitivity 2. Risk of iron overload such as chronic renal failure or thalassaemia major 3. Progressive disease 4. Bone marrow metastasis 5. Inability to monitor weekly complete blood counts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of blood transfusion at the consecutive cycle of chemotherapy between oral and intravenous iron, measured at the time of next cycle of chemotherapy (3 - 4 weeks depending on the chemotherapy regimen). | — |
Secondary
| Measure | Time frame |
|---|---|
| In both groups, assessed at the next cycle of chemotherapy (3 - 4 weeks depended on the chemotherapy regimen): 1. Haemoglobin and haematocrit increment 2. Number of blood transfusion units 3. Adverse events 4. Quality of life (QOL), also measured before treatment | — |
Countries
Thailand
Outcome results
None listed